About Hemanext
Hemanext is a company based in Lexington (United States) founded in 2004 by Martin Cannon. Hemanext has raised $127.57 million across 10 funding rounds from investors including HHS. The company has 53 employees as of December 31, 2021. Hemanext offers products and services including Hemanext ONE. Hemanext operates in a competitive market with competitors including Brooks Automation, Bridge to Life, Atelerix, Cellbox Solutions and Cold Chain Technologies, among others.
- Headquarter Lexington, United States
- Employees 53 as on 31 Dec, 2021
- Founders Martin Cannon
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hemanext, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$127.57 M (USD)
in 10 rounds
-
Latest Funding Round
$18.9 M (USD), Series B
Jul 22, 2025
- Investors
-
Employee Count
53
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hemanext
Hemanext offers a comprehensive portfolio of products and services, including Hemanext ONE.
Processes red blood cells to mitigate storage lesions and improve quality.
People of Hemanext
Unlock access to complete
Funding Insights of Hemanext
Hemanext has successfully raised a total of $127.57M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $18.9 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hemanext
Hemanext has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Hemanext
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hemanext
Investment portfolio details for Hemanext
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hemanext
Detailed financials for Hemanext
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hemanext Comparisons
Peer comparison for Hemanext
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hemanext
Hemanext operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brooks Automation, Bridge to Life, Atelerix, Cellbox Solutions and Cold Chain Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vacuum robots for semiconductor wafer handling are developed.
|
|
| Locked | Locked | Locked |
Cold storage solutions for organ transplant preservation are provided.
|
|
| Locked | Locked | Locked |
Technology for cell storage and transportation is developed.
|
|
| Locked | Locked | Locked |
Portable devices for cell storage and transport are provided.
|
|
| Locked | Locked | Locked |
Thermal packaging solutions and cold chain monitoring services are provided.
|
Detailed competitors of Hemanext
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hemanext
Complete news archive for Hemanext
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemanext
Hemanext was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Hemanext is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Andrew Dunham is the current CEO of Hemanext.
Hemanext is a funded company, having raised a total of $127.57M across 10 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Hemanext is 53.
Founded in 2004 and based in Lexington, United States, operations are focused on biotechnology for blood preservation. Two key technologies have been developed: Hemanext, which enables red blood cell storage under anaerobic conditions, and the MicroVascular Analyzer, used to measure red blood cell deformability. Applications include addressing hypercoagulability, inflammation, impaired perfusion, and immuno-modulation in therapeutic settings.
Hemanext's top competitors include Brooks Automation, Bridge to Life and Atelerix.
Hemanext offers Hemanext ONE.
Hemanext has 1 investor. Key investors include HHS.